Welcome to Vascular Pharmaceuticals
Vascular Pharmaceuticals (VPI) is a Delaware C-Corporation founded in 2005 with IP licensed from the University of North Carolina at Chapel Hill (UNC-CH) School of Medicine. VPI-2690B, a subcutaneously administered humanized mAb, is initiating a Phase 2 clinical trial for the treatment of diabetic nephropathy during the third quarter of 2014. The company completed its Series A financing in September 2012 with Intersouth Partners and MPM Capital as co-lead investors. In parallel with the Series A closing, VPI entered into a transaction that provides Janssen with the right to acquire VPI on pre-negotiated terms after the completion of the Phase 2 trial.